GlassScriptPhysician profile
Ethan A Natelson
NPI 1417921032
$5,796.83
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $336 · 2021: $349 · 2022: $1,366 · 2023: $1,587 · 2024: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $574.67 | 2022-2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $497.54 | 2019-2024 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $473.28 | 2019-2024 | |
| Celgene Corporation | $432.94 | 2019-2024 | Reblozyl, Pomalyst |
| Sobi, INC | $390.06 | 2022-2024 | |
| Amgen INC. | $378.38 | 2019-2023 | Xgeva, Nplate |
| Beigene USA, INC. | $290.90 | 2020-2024 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $287.98 | 2022-2024 | Empaveli |
| Genzyme Corporation | $225.36 | 2019-2024 | |
| Incyte Corporation | $221.33 | 2019-2024 | Jakafi |
| Pharmaessentia USA Corporation | $214.15 | 2022-2024 | Besremi |
| Pfizer INC. | $209.63 | 2019-2024 | |
| Daiichi Sankyo INC. | $158.66 | 2019-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $147.98 | 2020-2023 | Calquence |
| Janssen Biotech, INC. | $145.17 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Natelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.